Alliance for Regenerative Medicine Announces Agenda for Regen Med Investor Day
- Taking place April 17, 2013 in New York City; Agenda includes keynote talks, focused disease sessions with KOL participation and presentations from 16 top regenerative medicine companies -
WASHINGTON, March 12, 2013 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM) today announced the agenda for its Regen Med Investor Day, the first investor event organized specifically for the regenerative medicine sector. The event will take place on April 17 at the Harmonie Club, 4 East 60th Street, New York, NY.
This one-day, high-impact program will provide institutional investors and life science analysts with insight from the industry's leading small- and mid-cap companies as well as exclusive access to regenerative medicine's top stakeholders.
Credentialed investors, life science strategic partners and members of the media should contact Laura Parsons at [email protected] if interested in attending.
| 7:30am |
Breakfast & Networking |
|
| 8:00am |
Welcome Remarks |
|
| 8:10am |
Keynote Talk - Kieran Murphy, VP, President & CEO, GE Healthcare Life Sciences |
|
| 8:30am |
Keynote Talk - Jeff Jonas, President, Shire Regenerative Medicine |
|
| 8:50am |
Program Introduction - Jason Kolbert, Senior Biotechnology Analyst, Maxim Group |
|
| 9:00am |
Clinical Outlooks in Cardiovascular Disease |
|
| Jason Kolbert, Senior Biotechnology Analyst, Maxim Group (moderator) |
||
| Douglas Losordo, MD, Adjunct Professor in Medicine-Cardiology, Northwestern University |
||
| Eduardo Marban, MD, Director, Cedars-Sinai Heart Institute |
||
| Leslie Miller, MD, Chair, College Of Medicine Dean's Office, University of South Florida |
||
| 9:55am |
Break |
|
| 10:10am |
Regenerative Medicine in Wound Healing & Tissue Engineering |
|
| Ted Tenthoff, Managing Director & Senior Biotechnology Analyst, Piper Jaffray (moderator) |
||
| Vincent Falanga, MD, Professor, Boston University School of Medicine |
||
| Will Li, MD, President & Medical Director, The Angiogenesis Foundation |
||
| Thomas Serena, MD, FACS, CEO and Medical Director SerenaGroup |
||
| 11:05am |
Therapeutics for a Broad Range of CNS Diseases |
|
| Ren Benjamin, Ph.D., Managing Director & Senior Biotechnology Analyst, Burrill & Company (moderator) |
||
| Sean Savitz, MD, Professor of Neurology, University of Texas Medical School, UTHealth |
||
| 12:00pm |
Plated Lunch & Networking |
|
| 12:45pm |
Lunchtime Presentation - G. Steven Burrill, CEO, Burrill & Company |
|
| 1:00pm |
Cytori Therapeutics - Chris Calhoun, CEO |
|
| 1:15pm |
Athersys - Gil Van Bokkelen, Chairman & CEO |
|
| 1:30pm |
Mesoblast - Silviu Itescu, CEO & President |
|
| 1:45pm |
Juventas Therapeutics - Rahul Aras, President & CEO |
|
| 2:00pm |
Aastrom Biosciences - Dan Orlando, Chief Commercial Officer |
|
| 2:15pm |
NeoStem - Robin Smith, Chairman & CEO |
|
| 2:30pm |
Pluristem Therapeutics - Zami Aberman, Chairman & CEO |
|
| 2:45pm |
Cytomedix - Martin Rosendale, CEO |
|
| 3:00pm |
Afternoon Break |
|
| 3:15pm |
Sangamo BioSciences - Edward Lanphier, President & CEO |
|
| 3:30pm |
BioTime Acquisition Corp - Thomas Okarma, President & CEO |
|
| 3:45pm |
Advanced Cell Technology (ACT) - Gary Rabin, Chairman & CEO |
|
| 4:00pm |
StemCells Inc. - Martin McGlynn, President & CEO |
|
| 4:15pm |
Organogenesis - Geoff MacKay, President & CEO |
|
| 4:30pm |
Organovo - Keith Murphy, CEO |
|
| 4:45pm |
Tigenix - Eduardo Bravo, CEO |
|
| 5:00pm |
Mimedx - Michael Senken, CFO |
|
| 5:15pm |
Program Wrap-up - Ted Tenthoff, Managing Director & Senior Biotechnology |
|
| Analyst, Piper Jaffray |
||
| 5:30pm |
Networking Reception |
|
This meeting is co-hosted by leading financial firms Burrill & Company, Piper Jaffray and Maxim Group and in partnership with Life Science Advisors and Blaise Group International.
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.
Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087
SOURCE Alliance for Regenerative Medicine
Share this article